JP7278210B2 - ジストニアを治療するためのプリドピジンの使用 - Google Patents

ジストニアを治療するためのプリドピジンの使用 Download PDF

Info

Publication number
JP7278210B2
JP7278210B2 JP2019531546A JP2019531546A JP7278210B2 JP 7278210 B2 JP7278210 B2 JP 7278210B2 JP 2019531546 A JP2019531546 A JP 2019531546A JP 2019531546 A JP2019531546 A JP 2019531546A JP 7278210 B2 JP7278210 B2 JP 7278210B2
Authority
JP
Japan
Prior art keywords
dystonia
pridopidine
patients
baseline
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524897A (ja
JP2019524897A5 (enExample
Inventor
ヘイデン、マイケル
パパペトロパウロス、スピリドン
サヴォラ、ユハマッティ
エヤル、エリ
ボロウスキー、ベス
グラチェフ、イゴール・ディー
ゴードン、マーク・フォレスト
Original Assignee
プリレニア ニューロセラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プリレニア ニューロセラピューティクス リミテッド filed Critical プリレニア ニューロセラピューティクス リミテッド
Publication of JP2019524897A publication Critical patent/JP2019524897A/ja
Publication of JP2019524897A5 publication Critical patent/JP2019524897A5/ja
Priority to JP2021078788A priority Critical patent/JP7278327B2/ja
Application granted granted Critical
Publication of JP7278210B2 publication Critical patent/JP7278210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019531546A 2016-08-24 2017-08-24 ジストニアを治療するためのプリドピジンの使用 Active JP7278210B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078788A JP7278327B2 (ja) 2016-08-24 2021-05-06 ジストニアを治療するためのプリドピジンの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US62/379,175 2016-08-24
US201662395319P 2016-09-15 2016-09-15
US62/395,319 2016-09-15
PCT/US2017/048458 WO2018039475A1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating dystonias

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021078788A Division JP7278327B2 (ja) 2016-08-24 2021-05-06 ジストニアを治療するためのプリドピジンの使用

Publications (3)

Publication Number Publication Date
JP2019524897A JP2019524897A (ja) 2019-09-05
JP2019524897A5 JP2019524897A5 (enExample) 2019-10-17
JP7278210B2 true JP7278210B2 (ja) 2023-05-19

Family

ID=61246309

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531546A Active JP7278210B2 (ja) 2016-08-24 2017-08-24 ジストニアを治療するためのプリドピジンの使用
JP2021078788A Active JP7278327B2 (ja) 2016-08-24 2021-05-06 ジストニアを治療するためのプリドピジンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021078788A Active JP7278327B2 (ja) 2016-08-24 2021-05-06 ジストニアを治療するためのプリドピジンの使用

Country Status (12)

Country Link
US (2) US11826361B2 (enExample)
EP (1) EP3503890B1 (enExample)
JP (2) JP7278210B2 (enExample)
CN (1) CN110012661A (enExample)
AU (1) AU2017315781B2 (enExample)
BR (1) BR112019003731A2 (enExample)
CA (1) CA3035099C (enExample)
DK (1) DK3503890T3 (enExample)
ES (1) ES3009437T3 (enExample)
MX (1) MX2019002190A (enExample)
PL (1) PL3503890T3 (enExample)
WO (1) WO2018039475A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
JP7603713B2 (ja) * 2020-05-04 2024-12-20 プリレニア ニューロセラピューティクス リミテッド 選択的ｓ１ｒアゴニストを使用するウイルス感染、疾患、又は障害の治療
CN116472043A (zh) 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
KR20250121149A (ko) * 2022-12-27 2025-08-11 프리레니아 뉴로테라퓨틱스 엘티디. 소아 헌팅턴병 치료를 위한 프리도피딘
WO2024258929A1 (en) * 2023-06-12 2024-12-19 Unravel Biosciences, Inc. Methods for treating diseases associated with taf1 loss of function
WO2025188979A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds and pridopidine for treatment of huntington's disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523862A (ja) 2013-06-21 2016-08-12 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ ハンチントン病を治療するための高用量プリドピジンの使用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
CA2569843A1 (en) * 2004-06-08 2005-12-22 A. Carlsson Research Ab New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
MX2009011020A (es) 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
US8562488B2 (en) * 2009-10-05 2013-10-22 The Cleveland Clinic Foundation Systems and methods for improving motor function with assisted exercise
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX343620B (es) 2011-09-07 2016-11-11 Teva Pharmaceuticals Int Gmbh Forma polimorfica de clorhidrato de pridopidina.
EP2787997A4 (en) * 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
US20140037850A1 (en) * 2012-08-06 2014-02-06 General Electric Company Corrosion and wear resistant organic coatings
CA2937243C (en) 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3419622B1 (en) 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
ES2972205T3 (es) 2017-01-20 2024-06-11 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento del síndrome x frágil
HUE061505T2 (hu) 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523862A (ja) 2013-06-21 2016-08-12 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ ハンチントン病を治療するための高用量プリドピジンの使用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｎｅｕｒｏｌｏｇｙ， ２０１７， Ｖｏｌ．２４， ｐｐ．１１４０－１１４７
Ｌａｎｃｅｔ Ｎｅｕｒｏｌｏｇｙ，２０１１年，Ｖｏｌ．１０，ｐｐ．１０４９－１０５７
Ｍｏｖｅｍｅｎｔ Ｄｉｓｏｒｄｅｒｓ， １９９６， Ｖｏｌ．１１， Ｎｏ．２， ｐｐ．１３６－１４２
Ｍｏｖｅｍｅｎｔ Ｄｉｓｏｒｄｅｒｓ， ２０１３， Ｖｏｌ．２８， Ｎｏ．７， ｐｐ．８６３－８７３
Ｍｏｖｅｍｅｎｔ Ｄｉｓｏｒｄｅｒｓ， ２０１３， Ｖｏｌ．２８， Ｎｏ．７， ｐｐ．８７４－８８３
Ｎｅｕｒｏｌｏｇｙ， １９８５， Ｖｏｌ．３５， Ｎｏ．１， ｐｐ．７３－７７
日本臨床内科医会会誌，２０１５年，Ｖｏｌ．３０， Ｎｏｌ．２，ｐ．１７５
臨床神経学，２０１３年，Ｖｏｌ．５３， Ｎｏ．６，ｐｐ．４１９－４２９

Also Published As

Publication number Publication date
DK3503890T3 (da) 2025-01-27
AU2017315781A1 (en) 2019-04-11
EP3503890A4 (en) 2020-05-06
JP2019524897A (ja) 2019-09-05
US20240075021A1 (en) 2024-03-07
MX2019002190A (es) 2019-09-11
US12564582B2 (en) 2026-03-03
WO2018039475A8 (en) 2018-10-04
EP3503890A1 (en) 2019-07-03
CN110012661A (zh) 2019-07-12
WO2018039475A1 (en) 2018-03-01
CA3035099A1 (en) 2018-03-01
US20190192496A1 (en) 2019-06-27
AU2017315781B2 (en) 2021-01-28
JP2021119189A (ja) 2021-08-12
JP7278327B2 (ja) 2023-05-19
ES3009437T3 (en) 2025-03-26
PL3503890T3 (pl) 2025-03-24
BR112019003731A2 (pt) 2019-07-16
EP3503890B1 (en) 2024-12-18
CA3035099C (en) 2023-01-17
US11826361B2 (en) 2023-11-28

Similar Documents

Publication Publication Date Title
JP7278327B2 (ja) ジストニアを治療するためのプリドピジンの使用
US11207310B2 (en) Use of pridopidine for treating functional decline
US12390456B2 (en) Pridopidine for treating Huntington's disease
US20250352533A1 (en) Pridopidine for treating huntington's disease
WO2011107583A1 (en) Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20250319076A1 (en) Use of pridopidine and analogs for treating symptoms of huntington disease
HK40115915A (en) Use of pridopidine for treating functional decline
EA041256B1 (ru) Применение придопидина для лечения ухудшения функциональной способности
HK40009736A (en) Use of pridopidine for treating functional decline
HK40009736B (en) Use of pridopidine for treating functional decline
NZ751156B2 (en) Use of pridopidine for treating functional decline
NZ791717A (en) Use of pridopidine for treating functional decline

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210506

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210506

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210518

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210525

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210618

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210622

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220412

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20221004

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221228

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230201

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230307

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230411

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230509

R150 Certificate of patent or registration of utility model

Ref document number: 7278210

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250